KR20190046825A - 조기 양막 파열 대 특발성 자연 진통으로 인한 조산 예측용 바이오마커 - Google Patents
조기 양막 파열 대 특발성 자연 진통으로 인한 조산 예측용 바이오마커 Download PDFInfo
- Publication number
- KR20190046825A KR20190046825A KR1020197006188A KR20197006188A KR20190046825A KR 20190046825 A KR20190046825 A KR 20190046825A KR 1020197006188 A KR1020197006188 A KR 1020197006188A KR 20197006188 A KR20197006188 A KR 20197006188A KR 20190046825 A KR20190046825 A KR 20190046825A
- Authority
- KR
- South Korea
- Prior art keywords
- biomarkers
- biomarker
- birth
- pprom
- preterm
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000000090 biomarker Substances 0.000 title claims abstract description 203
- 206010036603 Premature rupture of membranes Diseases 0.000 title claims abstract description 81
- 208000005107 Premature Birth Diseases 0.000 title claims abstract description 80
- 230000036407 pain Effects 0.000 title claims abstract description 7
- 206010036590 Premature baby Diseases 0.000 title description 50
- 238000000034 method Methods 0.000 claims abstract description 200
- 238000012384 transportation and delivery Methods 0.000 claims abstract description 42
- 239000012472 biological sample Substances 0.000 claims description 48
- 239000000203 mixture Substances 0.000 abstract description 22
- 230000002028 premature Effects 0.000 abstract description 9
- 108090000623 proteins and genes Proteins 0.000 description 86
- 102000004169 proteins and genes Human genes 0.000 description 85
- 208000006399 Premature Obstetric Labor Diseases 0.000 description 70
- 230000035935 pregnancy Effects 0.000 description 67
- 238000004949 mass spectrometry Methods 0.000 description 65
- 108090000765 processed proteins & peptides Proteins 0.000 description 61
- 238000004458 analytical method Methods 0.000 description 49
- 102000004196 processed proteins & peptides Human genes 0.000 description 37
- 239000003795 chemical substances by application Substances 0.000 description 36
- 239000012491 analyte Substances 0.000 description 34
- 239000000523 sample Substances 0.000 description 32
- 230000001105 regulatory effect Effects 0.000 description 29
- 238000003556 assay Methods 0.000 description 26
- 238000004422 calculation algorithm Methods 0.000 description 26
- 238000001514 detection method Methods 0.000 description 26
- 125000000539 amino acid group Chemical group 0.000 description 21
- 238000002552 multiple reaction monitoring Methods 0.000 description 20
- 230000000875 corresponding effect Effects 0.000 description 18
- 210000002966 serum Anatomy 0.000 description 18
- 108091023037 Aptamer Proteins 0.000 description 16
- 239000003153 chemical reaction reagent Substances 0.000 description 16
- 230000014509 gene expression Effects 0.000 description 16
- 230000008774 maternal effect Effects 0.000 description 16
- 230000027455 binding Effects 0.000 description 15
- 239000012634 fragment Substances 0.000 description 15
- 238000011002 quantification Methods 0.000 description 15
- 206010057190 Respiratory tract infections Diseases 0.000 description 14
- 238000005259 measurement Methods 0.000 description 14
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 13
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 12
- 238000002553 single reaction monitoring Methods 0.000 description 12
- 230000036541 health Effects 0.000 description 11
- 238000003018 immunoassay Methods 0.000 description 11
- 230000008569 process Effects 0.000 description 11
- 238000003127 radioimmunoassay Methods 0.000 description 11
- 238000013459 approach Methods 0.000 description 10
- 230000008901 benefit Effects 0.000 description 10
- 238000004587 chromatography analysis Methods 0.000 description 10
- 238000009826 distribution Methods 0.000 description 10
- 238000012544 monitoring process Methods 0.000 description 10
- 108020004707 nucleic acids Proteins 0.000 description 10
- 102000039446 nucleic acids Human genes 0.000 description 10
- 150000007523 nucleic acids Chemical class 0.000 description 10
- 238000012360 testing method Methods 0.000 description 9
- 210000004369 blood Anatomy 0.000 description 8
- 239000008280 blood Substances 0.000 description 8
- 238000005516 engineering process Methods 0.000 description 8
- 239000000463 material Substances 0.000 description 8
- 229920001184 polypeptide Polymers 0.000 description 8
- 230000035945 sensitivity Effects 0.000 description 8
- -1 but not limited to Substances 0.000 description 7
- 208000037805 labour Diseases 0.000 description 7
- 238000010606 normalization Methods 0.000 description 7
- 238000000611 regression analysis Methods 0.000 description 7
- 230000004044 response Effects 0.000 description 7
- 108010079003 sodium-influx-stimulating peptide Proteins 0.000 description 7
- 102000004190 Enzymes Human genes 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- 206010020772 Hypertension Diseases 0.000 description 6
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 6
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 6
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 6
- 150000001413 amino acids Chemical class 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 6
- 230000002596 correlated effect Effects 0.000 description 6
- 150000002500 ions Chemical class 0.000 description 6
- 238000007477 logistic regression Methods 0.000 description 6
- 108020004999 messenger RNA Proteins 0.000 description 6
- 230000037361 pathway Effects 0.000 description 6
- 238000007637 random forest analysis Methods 0.000 description 6
- 238000003757 reverse transcription PCR Methods 0.000 description 6
- 238000012549 training Methods 0.000 description 6
- 238000000018 DNA microarray Methods 0.000 description 5
- 101000840572 Homo sapiens Insulin-like growth factor-binding protein 4 Proteins 0.000 description 5
- 102100029224 Insulin-like growth factor-binding protein 4 Human genes 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 238000004811 liquid chromatography Methods 0.000 description 5
- 239000003550 marker Substances 0.000 description 5
- 238000002493 microarray Methods 0.000 description 5
- 150000003384 small molecules Chemical class 0.000 description 5
- 239000000758 substrate Substances 0.000 description 5
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 4
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 4
- 208000001362 Fetal Growth Retardation Diseases 0.000 description 4
- 230000005526 G1 to G0 transition Effects 0.000 description 4
- 208000034702 Multiple pregnancies Diseases 0.000 description 4
- 108091005804 Peptidases Proteins 0.000 description 4
- 206010036600 Premature labour Diseases 0.000 description 4
- 239000004365 Protease Substances 0.000 description 4
- 108010089417 Sex Hormone-Binding Globulin Proteins 0.000 description 4
- 102100030758 Sex hormone-binding globulin Human genes 0.000 description 4
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
- 108090000631 Trypsin Proteins 0.000 description 4
- 102000004142 Trypsin Human genes 0.000 description 4
- 230000000740 bleeding effect Effects 0.000 description 4
- 230000002950 deficient Effects 0.000 description 4
- 238000003795 desorption Methods 0.000 description 4
- 206010012601 diabetes mellitus Diseases 0.000 description 4
- 230000029087 digestion Effects 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 230000035558 fertility Effects 0.000 description 4
- 208000030941 fetal growth restriction Diseases 0.000 description 4
- 238000013467 fragmentation Methods 0.000 description 4
- 238000006062 fragmentation reaction Methods 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 229940088597 hormone Drugs 0.000 description 4
- 239000005556 hormone Substances 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000004005 microsphere Substances 0.000 description 4
- 238000003199 nucleic acid amplification method Methods 0.000 description 4
- 239000002773 nucleotide Substances 0.000 description 4
- 125000003729 nucleotide group Chemical group 0.000 description 4
- 230000003169 placental effect Effects 0.000 description 4
- 210000002381 plasma Anatomy 0.000 description 4
- 239000002243 precursor Substances 0.000 description 4
- 208000026440 premature labor Diseases 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- 150000003431 steroids Chemical class 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- 230000007704 transition Effects 0.000 description 4
- 239000012588 trypsin Substances 0.000 description 4
- 238000002604 ultrasonography Methods 0.000 description 4
- 206010048828 underweight Diseases 0.000 description 4
- 208000010422 uterine anomalies Diseases 0.000 description 4
- 206010000234 Abortion spontaneous Diseases 0.000 description 3
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 206010073024 Preterm premature rupture of membranes Diseases 0.000 description 3
- 238000011529 RT qPCR Methods 0.000 description 3
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 3
- 206010000210 abortion Diseases 0.000 description 3
- 231100000176 abortion Toxicity 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 210000004381 amniotic fluid Anatomy 0.000 description 3
- 208000006673 asthma Diseases 0.000 description 3
- 238000000668 atmospheric pressure chemical ionisation mass spectrometry Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- RGLYKWWBQGJZGM-ISLYRVAYSA-N diethylstilbestrol Chemical compound C=1C=C(O)C=CC=1C(/CC)=C(\CC)C1=CC=C(O)C=C1 RGLYKWWBQGJZGM-ISLYRVAYSA-N 0.000 description 3
- 229960000452 diethylstilbestrol Drugs 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 3
- 230000008030 elimination Effects 0.000 description 3
- 238000003379 elimination reaction Methods 0.000 description 3
- 230000001605 fetal effect Effects 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 238000010801 machine learning Methods 0.000 description 3
- 238000007726 management method Methods 0.000 description 3
- 238000000816 matrix-assisted laser desorption--ionisation Methods 0.000 description 3
- 239000011859 microparticle Substances 0.000 description 3
- 230000036961 partial effect Effects 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 102000040430 polynucleotide Human genes 0.000 description 3
- 108091033319 polynucleotide Proteins 0.000 description 3
- 239000002157 polynucleotide Substances 0.000 description 3
- 201000011461 pre-eclampsia Diseases 0.000 description 3
- 208000008881 preterm premature rupture of the membranes Diseases 0.000 description 3
- 239000000186 progesterone Substances 0.000 description 3
- 229960003387 progesterone Drugs 0.000 description 3
- 239000002096 quantum dot Substances 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 230000002441 reversible effect Effects 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 208000000995 spontaneous abortion Diseases 0.000 description 3
- 230000002269 spontaneous effect Effects 0.000 description 3
- 238000007619 statistical method Methods 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 238000004885 tandem mass spectrometry Methods 0.000 description 3
- 230000000007 visual effect Effects 0.000 description 3
- 230000036266 weeks of gestation Effects 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- 102100021834 3-hydroxyacyl-CoA dehydrogenase Human genes 0.000 description 2
- 102100028042 Alpha-2-HS-glycoprotein Human genes 0.000 description 2
- 102100030970 Apolipoprotein C-III Human genes 0.000 description 2
- 102100030802 Beta-2-glycoprotein 1 Human genes 0.000 description 2
- 102100038285 Endogenous retroviral envelope protein HEMO Human genes 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 238000000729 Fisher's exact test Methods 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 2
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 2
- 101001060288 Homo sapiens Alpha-2-HS-glycoprotein Proteins 0.000 description 2
- 101000793223 Homo sapiens Apolipoprotein C-III Proteins 0.000 description 2
- 101000793425 Homo sapiens Beta-2-glycoprotein 1 Proteins 0.000 description 2
- 101001033183 Homo sapiens Endogenous retroviral envelope protein HEMO Proteins 0.000 description 2
- 101001035951 Homo sapiens Hyaluronan-binding protein 2 Proteins 0.000 description 2
- 101001091590 Homo sapiens Kininogen-1 Proteins 0.000 description 2
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 2
- 101000617726 Homo sapiens Pregnancy-specific beta-1-glycoprotein 3 Proteins 0.000 description 2
- 101000881247 Homo sapiens Spectrin beta chain, erythrocytic Proteins 0.000 description 2
- 102100039238 Hyaluronan-binding protein 2 Human genes 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 102100035792 Kininogen-1 Human genes 0.000 description 2
- 101710089435 Lipopolysaccharide-binding protein Proteins 0.000 description 2
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- 102100033073 Polypyrimidine tract-binding protein 1 Human genes 0.000 description 2
- 102100022020 Pregnancy-specific beta-1-glycoprotein 3 Human genes 0.000 description 2
- 108010029485 Protein Isoforms Proteins 0.000 description 2
- 102000001708 Protein Isoforms Human genes 0.000 description 2
- 108010026552 Proteome Proteins 0.000 description 2
- 102100037613 Spectrin beta chain, erythrocytic Human genes 0.000 description 2
- 208000035010 Term birth Diseases 0.000 description 2
- 238000001793 Wilcoxon signed-rank test Methods 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 210000000577 adipose tissue Anatomy 0.000 description 2
- 239000003463 adsorbent Substances 0.000 description 2
- 238000001042 affinity chromatography Methods 0.000 description 2
- 125000003275 alpha amino acid group Chemical group 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 238000000889 atomisation Methods 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 230000006399 behavior Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 102000005936 beta-Galactosidase Human genes 0.000 description 2
- 108010005774 beta-Galactosidase Proteins 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 238000002045 capillary electrochromatography Methods 0.000 description 2
- 238000001818 capillary gel electrophoresis Methods 0.000 description 2
- 238000000533 capillary isoelectric focusing Methods 0.000 description 2
- 238000001649 capillary isotachophoresis Methods 0.000 description 2
- 238000005515 capillary zone electrophoresis Methods 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 210000003756 cervix mucus Anatomy 0.000 description 2
- 210000003679 cervix uteri Anatomy 0.000 description 2
- 238000000546 chi-square test Methods 0.000 description 2
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 2
- 238000001360 collision-induced dissociation Methods 0.000 description 2
- 230000002860 competitive effect Effects 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 238000002790 cross-validation Methods 0.000 description 2
- 238000007405 data analysis Methods 0.000 description 2
- 238000013501 data transformation Methods 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 230000002996 emotional effect Effects 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 230000008175 fetal development Effects 0.000 description 2
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 2
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 2
- 238000005194 fractionation Methods 0.000 description 2
- 238000001997 free-flow electrophoresis Methods 0.000 description 2
- 238000002290 gas chromatography-mass spectrometry Methods 0.000 description 2
- 208000004104 gestational diabetes Diseases 0.000 description 2
- 239000005090 green fluorescent protein Substances 0.000 description 2
- 238000002013 hydrophilic interaction chromatography Methods 0.000 description 2
- 238000004191 hydrophobic interaction chromatography Methods 0.000 description 2
- 208000003532 hypothyroidism Diseases 0.000 description 2
- 230000002989 hypothyroidism Effects 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 238000010166 immunofluorescence Methods 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 238000003364 immunohistochemistry Methods 0.000 description 2
- 238000001114 immunoprecipitation Methods 0.000 description 2
- 238000001095 inductively coupled plasma mass spectrometry Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 238000004255 ion exchange chromatography Methods 0.000 description 2
- 238000001155 isoelectric focusing Methods 0.000 description 2
- 150000002540 isothiocyanates Chemical class 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 230000035800 maturation Effects 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000003821 menstrual periods Effects 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 239000011325 microbead Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 239000002159 nanocrystal Substances 0.000 description 2
- 238000004305 normal phase HPLC Methods 0.000 description 2
- 239000002777 nucleoside Substances 0.000 description 2
- 125000003835 nucleoside group Chemical group 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 238000003068 pathway analysis Methods 0.000 description 2
- 230000037081 physical activity Effects 0.000 description 2
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 2
- 238000003752 polymerase chain reaction Methods 0.000 description 2
- 102000054765 polymorphisms of proteins Human genes 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 230000007065 protein hydrolysis Effects 0.000 description 2
- 238000004445 quantitative analysis Methods 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 238000004007 reversed phase HPLC Methods 0.000 description 2
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 2
- 210000003296 saliva Anatomy 0.000 description 2
- 238000001542 size-exclusion chromatography Methods 0.000 description 2
- 230000000391 smoking effect Effects 0.000 description 2
- 230000009870 specific binding Effects 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 238000012706 support-vector machine Methods 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000009897 systematic effect Effects 0.000 description 2
- MPLHNVLQVRSVEE-UHFFFAOYSA-N texas red Chemical compound [O-]S(=O)(=O)C1=CC(S(Cl)(=O)=O)=CC=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 MPLHNVLQVRSVEE-UHFFFAOYSA-N 0.000 description 2
- 238000001195 ultra high performance liquid chromatography Methods 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 206010046901 vaginal discharge Diseases 0.000 description 2
- DBPWSSGDRRHUNT-CEGNMAFCSA-N 17α-hydroxyprogesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)C)(O)[C@@]1(C)CC2 DBPWSSGDRRHUNT-CEGNMAFCSA-N 0.000 description 1
- VGIRNWJSIRVFRT-UHFFFAOYSA-N 2',7'-difluorofluorescein Chemical compound OC(=O)C1=CC=CC=C1C1=C2C=C(F)C(=O)C=C2OC2=CC(O)=C(F)C=C21 VGIRNWJSIRVFRT-UHFFFAOYSA-N 0.000 description 1
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 206010048998 Acute phase reaction Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 102000008025 CLOCK Proteins Human genes 0.000 description 1
- 108010075228 CLOCK Proteins Proteins 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 235000012766 Cannabis sativa ssp. sativa var. sativa Nutrition 0.000 description 1
- 235000012765 Cannabis sativa ssp. sativa var. spontanea Nutrition 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- 239000003155 DNA primer Substances 0.000 description 1
- SHIBSTMRCDJXLN-UHFFFAOYSA-N Digoxigenin Natural products C1CC(C2C(C3(C)CCC(O)CC3CC2)CC2O)(O)C2(C)C1C1=CC(=O)OC1 SHIBSTMRCDJXLN-UHFFFAOYSA-N 0.000 description 1
- 102100021977 Ectonucleotide pyrophosphatase/phosphodiesterase family member 2 Human genes 0.000 description 1
- 108010008177 Fd immunoglobulins Proteins 0.000 description 1
- 206010061182 Genitourinary tract infection Diseases 0.000 description 1
- 208000035223 Gestational Weight Gain Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 101000897035 Homo sapiens Ectonucleotide pyrophosphatase/phosphodiesterase family member 2 Proteins 0.000 description 1
- 101001076292 Homo sapiens Insulin-like growth factor II Proteins 0.000 description 1
- 101001044927 Homo sapiens Insulin-like growth factor-binding protein 3 Proteins 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102100025947 Insulin-like growth factor II Human genes 0.000 description 1
- 102100022708 Insulin-like growth factor-binding protein 3 Human genes 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 238000007476 Maximum Likelihood Methods 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 108010085220 Multiprotein Complexes Proteins 0.000 description 1
- 102000007474 Multiprotein Complexes Human genes 0.000 description 1
- 101100478282 Mus musculus Sptb gene Proteins 0.000 description 1
- 102000005348 Neuraminidase Human genes 0.000 description 1
- 108010006232 Neuraminidase Proteins 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 206010073310 Occupational exposures Diseases 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 206010033307 Overweight Diseases 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108010033276 Peptide Fragments Proteins 0.000 description 1
- 102000007079 Peptide Fragments Human genes 0.000 description 1
- 108010043958 Peptoids Proteins 0.000 description 1
- 241001495084 Phylo Species 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 206010036877 Prolonged Pregnancy Diseases 0.000 description 1
- 108010081734 Ribonucleoproteins Proteins 0.000 description 1
- 102000004389 Ribonucleoproteins Human genes 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 208000037063 Thinness Diseases 0.000 description 1
- 108010046334 Urease Proteins 0.000 description 1
- 208000036029 Uterine contractions during pregnancy Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000004658 acute-phase response Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 238000005349 anion exchange Methods 0.000 description 1
- 238000005571 anion exchange chromatography Methods 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000008238 biochemical pathway Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000008236 biological pathway Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 208000034158 bleeding Diseases 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 238000005251 capillar electrophoresis Methods 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000005277 cation exchange chromatography Methods 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 150000005829 chemical entities Chemical class 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 201000001883 cholelithiasis Diseases 0.000 description 1
- 238000011098 chromatofocusing Methods 0.000 description 1
- 239000003593 chromogenic compound Substances 0.000 description 1
- 238000007635 classification algorithm Methods 0.000 description 1
- 238000013145 classification model Methods 0.000 description 1
- 238000000749 co-immunoprecipitation Methods 0.000 description 1
- 229960003920 cocaine Drugs 0.000 description 1
- 230000001149 cognitive effect Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 238000002967 competitive immunoassay Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 108050003126 conotoxin Proteins 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000000326 densiometry Methods 0.000 description 1
- 230000000779 depleting effect Effects 0.000 description 1
- 238000009795 derivation Methods 0.000 description 1
- 238000011033 desalting Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 235000018823 dietary intake Nutrition 0.000 description 1
- QONQRTHLHBTMGP-UHFFFAOYSA-N digitoxigenin Natural products CC12CCC(C3(CCC(O)CC3CC3)C)C3C11OC1CC2C1=CC(=O)OC1 QONQRTHLHBTMGP-UHFFFAOYSA-N 0.000 description 1
- SHIBSTMRCDJXLN-KCZCNTNESA-N digoxigenin Chemical compound C1([C@@H]2[C@@]3([C@@](CC2)(O)[C@H]2[C@@H]([C@@]4(C)CC[C@H](O)C[C@H]4CC2)C[C@H]3O)C)=CC(=O)OC1 SHIBSTMRCDJXLN-KCZCNTNESA-N 0.000 description 1
- BFMYDTVEBKDAKJ-UHFFFAOYSA-L disodium;(2',7'-dibromo-3',6'-dioxido-3-oxospiro[2-benzofuran-1,9'-xanthene]-4'-yl)mercury;hydrate Chemical compound O.[Na+].[Na+].O1C(=O)C2=CC=CC=C2C21C1=CC(Br)=C([O-])C([Hg])=C1OC1=C2C=C(Br)C([O-])=C1 BFMYDTVEBKDAKJ-UHFFFAOYSA-L 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 238000009547 dual-energy X-ray absorptiometry Methods 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000004193 electrokinetic chromatography Methods 0.000 description 1
- 238000002101 electrospray ionisation tandem mass spectrometry Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000003114 enzyme-linked immunosorbent spot assay Methods 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000004299 exfoliation Methods 0.000 description 1
- 210000001808 exosome Anatomy 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000004578 fetal growth Effects 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 238000001641 gel filtration chromatography Methods 0.000 description 1
- 238000005227 gel permeation chromatography Methods 0.000 description 1
- 238000011223 gene expression profiling Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-M hexanoate Chemical compound CCCCCC([O-])=O FUZZWVXGSFPDMH-UHFFFAOYSA-M 0.000 description 1
- 238000001597 immobilized metal affinity chromatography Methods 0.000 description 1
- 230000006058 immune tolerance Effects 0.000 description 1
- 230000000984 immunochemical effect Effects 0.000 description 1
- 238000003318 immunodepletion Methods 0.000 description 1
- 238000012001 immunoprecipitation mass spectrometry Methods 0.000 description 1
- 239000003547 immunosorbent Substances 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 208000000509 infertility Diseases 0.000 description 1
- 231100000535 infertility Toxicity 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- PGLTVOMIXTUURA-UHFFFAOYSA-N iodoacetamide Chemical compound NC(=O)CI PGLTVOMIXTUURA-UHFFFAOYSA-N 0.000 description 1
- 238000005040 ion trap Methods 0.000 description 1
- 238000000534 ion trap mass spectrometry Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000001948 isotopic labelling Methods 0.000 description 1
- 201000003723 learning disability Diseases 0.000 description 1
- 230000005034 leisure-time physical activity Effects 0.000 description 1
- 238000007834 ligase chain reaction Methods 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 208000018773 low birth weight Diseases 0.000 description 1
- 231100000533 low birth weight Toxicity 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000007040 lung development Effects 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 229940015467 makena Drugs 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000000074 matrix-assisted laser desorption--ionisation tandem time-of-flight detection Methods 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 230000002175 menstrual effect Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000002082 metal nanoparticle Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 230000003990 molecular pathway Effects 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 238000007837 multiplex assay Methods 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 238000002414 normal-phase solid-phase extraction Methods 0.000 description 1
- 231100000675 occupational exposure Toxicity 0.000 description 1
- 239000002751 oligonucleotide probe Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- INAAIJLSXJJHOZ-UHFFFAOYSA-N pibenzimol Chemical compound C1CN(C)CCN1C1=CC=C(N=C(N2)C=3C=C4NC(=NC4=CC=3)C=3C=CC(O)=CC=3)C2=C1 INAAIJLSXJJHOZ-UHFFFAOYSA-N 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 238000013439 planning Methods 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 229940043274 prophylactic drug Drugs 0.000 description 1
- 239000012658 prophylactic medication Substances 0.000 description 1
- 238000001303 quality assessment method Methods 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 238000010833 quantitative mass spectrometry Methods 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000026267 regulation of growth Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 238000012502 risk assessment Methods 0.000 description 1
- 238000003118 sandwich ELISA Methods 0.000 description 1
- 238000001004 secondary ion mass spectrometry Methods 0.000 description 1
- 238000012882 sequential analysis Methods 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 125000005629 sialic acid group Chemical group 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 238000004088 simulation Methods 0.000 description 1
- 230000005586 smoking cessation Effects 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 208000002254 stillbirth Diseases 0.000 description 1
- 231100000537 stillbirth Toxicity 0.000 description 1
- 210000004003 subcutaneous fat Anatomy 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000004416 surface enhanced Raman spectroscopy Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000010409 thin film Substances 0.000 description 1
- 238000001269 time-of-flight mass spectrometry Methods 0.000 description 1
- 229940125712 tocolytic agent Drugs 0.000 description 1
- 239000003675 tocolytic agent Substances 0.000 description 1
- 230000003195 tocolytic effect Effects 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 238000005109 two-dimensional liquid chromatography tandem mass spectrometry Methods 0.000 description 1
- 238000007473 univariate analysis Methods 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 208000019206 urinary tract infection Diseases 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
- G01N33/6848—Methods of protein analysis involving mass spectrometry
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B40/00—Libraries per se, e.g. arrays, mixtures
- C40B40/04—Libraries containing only organic compounds
- C40B40/10—Libraries containing peptides or polypeptides, or derivatives thereof
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/689—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to pregnancy or the gonads
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2560/00—Chemical aspects of mass spectrometric analysis of biological material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2570/00—Omics, e.g. proteomics, glycomics or lipidomics; Methods of analysis focusing on the entire complement of classes of biological molecules or subsets thereof, i.e. focusing on proteomes, glycomes or lipidomes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/36—Gynecology or obstetrics
- G01N2800/368—Pregnancy complicated by disease or abnormalities of pregnancy, e.g. preeclampsia, preterm labour
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Organic Chemistry (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pathology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Bioinformatics & Computational Biology (AREA)
- Biophysics (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Pregnancy & Childbirth (AREA)
- Gynecology & Obstetrics (AREA)
- Reproductive Health (AREA)
- Spectroscopy & Molecular Physics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Engineering & Computer Science (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662371666P | 2016-08-05 | 2016-08-05 | |
| US62/371,666 | 2016-08-05 | ||
| US201762449862P | 2017-01-24 | 2017-01-24 | |
| US62/449,862 | 2017-01-24 | ||
| PCT/US2017/045576 WO2018027171A1 (en) | 2016-08-05 | 2017-08-04 | Biomarkers for predicting preterm birth due to preterm premature rupture of membranes versus idiopathic spontaneous labor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20190046825A true KR20190046825A (ko) | 2019-05-07 |
Family
ID=61073085
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020197006188A Withdrawn KR20190046825A (ko) | 2016-08-05 | 2017-08-04 | 조기 양막 파열 대 특발성 자연 진통으로 인한 조산 예측용 바이오마커 |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US20180172698A1 (enExample) |
| EP (1) | EP3494233A4 (enExample) |
| JP (2) | JP2019532261A (enExample) |
| KR (1) | KR20190046825A (enExample) |
| CN (1) | CN110191963A (enExample) |
| AU (1) | AU2017307584A1 (enExample) |
| CA (1) | CA3032754A1 (enExample) |
| IL (1) | IL264576A (enExample) |
| RU (1) | RU2019105691A (enExample) |
| WO (1) | WO2018027171A1 (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11664100B2 (en) * | 2021-08-17 | 2023-05-30 | Birth Model, Inc. | Predicting time to vaginal delivery |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2724013C2 (ru) | 2015-06-19 | 2020-06-18 | Сера Прогностикс, Инк. | Пары биологических маркеров для предсказания преждевременных родов |
| WO2019036032A1 (en) * | 2017-08-18 | 2019-02-21 | Sera Prognostics, Inc | PREGNANCY CLOCK PROTEINS FOR PREDICTING THE DATE AND MOMENT OF BIRTH |
| TW201923347A (zh) * | 2017-10-30 | 2019-06-16 | 新加坡商卡曼提克斯有限公司 | 早產之生物標記 |
| WO2021252595A1 (en) * | 2020-06-10 | 2021-12-16 | Board Of Regents, The University Of Texas System | Method for determining risk of pre-term birth |
| WO2022098839A1 (en) * | 2020-11-05 | 2022-05-12 | Board Of Regents, The University Of Texas System | Individual optimal mode of delivery |
| WO2022246288A2 (en) * | 2021-05-21 | 2022-11-24 | Sera Prognostics, Inc. | Biomarker pairs and triplets for predicting preterm birth |
| RU2763707C1 (ru) * | 2021-06-01 | 2021-12-30 | Наталья Борисовна Кузнецова | Способ прогнозирования преждевременного разрыва плодных оболочек в сроке от 22 до 28 недель беременности |
| WO2023102786A1 (zh) * | 2021-12-08 | 2023-06-15 | 深圳华大基因股份有限公司 | 基因标志物在预测孕妇早产风险中的应用 |
| WO2024156709A1 (en) * | 2023-01-24 | 2024-08-02 | Université Clermont Auvergne | Evaluation of serum cx3cl1 for the prediction of preterm premature rupture of membranes |
| WO2024182491A1 (en) * | 2023-02-28 | 2024-09-06 | Virginia Commonwealth University | Polygenic risk estimator for cervical length change during pregnancy |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050233400A1 (en) * | 2004-03-03 | 2005-10-20 | Weiner Carl P | Proteomic method for predicting success of rescue cerclage |
| RU2586412C2 (ru) * | 2012-06-09 | 2016-06-10 | Общество с ограниченной ответственностью научно-технический центр "БиоКлиникум" (ООО НТЦ "БиоКлиникум") | Способ оценки риска возникновения патологии беременности |
| US20140186332A1 (en) * | 2012-12-28 | 2014-07-03 | NX Pharmagen | Biomarkers of preterm birth |
| WO2014110098A1 (en) * | 2013-01-08 | 2014-07-17 | Duke University | Biomarkers for the prediction of preterm birth |
| CA2907120C (en) * | 2013-03-15 | 2023-10-17 | Sera Prognostics, Inc. | Biomarkers and methods for predicting preterm birth |
| US20140287948A1 (en) * | 2013-03-15 | 2014-09-25 | Sera Prognostics, Inc. | Biomarkers and methods for predicting preterm birth |
| CA3210007A1 (en) * | 2013-03-15 | 2014-09-18 | Sera Prognostics, Inc | Biomarkers and methods for predicting preeclampsia |
| RU2724013C2 (ru) * | 2015-06-19 | 2020-06-18 | Сера Прогностикс, Инк. | Пары биологических маркеров для предсказания преждевременных родов |
-
2017
- 2017-08-04 RU RU2019105691A patent/RU2019105691A/ru not_active Application Discontinuation
- 2017-08-04 AU AU2017307584A patent/AU2017307584A1/en not_active Abandoned
- 2017-08-04 JP JP2019505476A patent/JP2019532261A/ja not_active Withdrawn
- 2017-08-04 EP EP17837787.5A patent/EP3494233A4/en not_active Withdrawn
- 2017-08-04 KR KR1020197006188A patent/KR20190046825A/ko not_active Withdrawn
- 2017-08-04 US US15/669,746 patent/US20180172698A1/en not_active Abandoned
- 2017-08-04 CN CN201780062065.0A patent/CN110191963A/zh active Pending
- 2017-08-04 CA CA3032754A patent/CA3032754A1/en active Pending
- 2017-08-04 WO PCT/US2017/045576 patent/WO2018027171A1/en not_active Ceased
-
2019
- 2019-01-31 IL IL264576A patent/IL264576A/en unknown
-
2020
- 2020-08-05 US US16/986,044 patent/US20210190792A1/en not_active Abandoned
-
2022
- 2022-07-15 JP JP2022113886A patent/JP2022140511A/ja active Pending
-
2024
- 2024-06-17 US US18/745,657 patent/US20250085293A1/en active Pending
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11664100B2 (en) * | 2021-08-17 | 2023-05-30 | Birth Model, Inc. | Predicting time to vaginal delivery |
| US12133741B2 (en) | 2021-08-17 | 2024-11-05 | Birth Model, Inc. | Predicting time to vaginal delivery |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2019532261A (ja) | 2019-11-07 |
| US20180172698A1 (en) | 2018-06-21 |
| EP3494233A1 (en) | 2019-06-12 |
| CA3032754A1 (en) | 2018-02-08 |
| IL264576A (en) | 2019-02-28 |
| CN110191963A (zh) | 2019-08-30 |
| US20210190792A1 (en) | 2021-06-24 |
| RU2019105691A (ru) | 2020-09-08 |
| EP3494233A4 (en) | 2020-03-18 |
| JP2022140511A (ja) | 2022-09-26 |
| AU2017307584A1 (en) | 2019-03-21 |
| WO2018027171A1 (en) | 2018-02-08 |
| US20250085293A1 (en) | 2025-03-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7412790B2 (ja) | 早産を予測するためのバイオマーカーおよび方法 | |
| US20240318250A1 (en) | Biomarker pairs for predicting preterm birth | |
| US20250085293A1 (en) | Biomarkers for predicting preterm birth due to preterm premature rupture of membranes (pprom) versus idiopathic spontaneous labor (ptl) | |
| US20230408530A1 (en) | Pregnancy clock proteins for predicting due date and time to birth | |
| US20190369109A1 (en) | Biomarkers for predicting preterm birth in a pregnant female exposed to progestogens | |
| US20240264170A1 (en) | Biomarker pairs and triplets for predicting preterm birth | |
| WO2025137134A1 (en) | Biomarkers for predicting due date and time to birth | |
| HK40107594A (en) | Biomarker pairs for predicting preterm birth | |
| HK40081224A (en) | Biomarker pairs for predicting preterm birth | |
| HK1254669B (en) | Biomarker pairs for predicting preterm birth |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20190228 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| PC1203 | Withdrawal of no request for examination |